Last checked at 1 Nov 2019 07:00
Spire Healthcare Group plc
("Spire Healthcare", "the Company" or "the Group")
Completion of disposal
Spire Healthcare (LSE: SPI), a leading independent hospital group in the UK, today announces the completion of the sale of two Spire sites, Baddow Specialist Care Centre and Bristol Cancer Centre, for a total consideration of £12.0 million to GenesisCare.
As announced on 16 September 2019, the sale of the two sites completes the first step of the new partnership between Spire Healthcare and GenesisCare to create a national end-to-end private cancer care pathway. As part of the partnership, Spire Healthcare will retain 50% share of chemotherapy gross profits generated at Bristol Cancer Centre and will provide diagnostics and surgery for this location. GenesisCare will contribute its leading expertise in radiotherapy, treatment planning, and innovation in areas such as its electronic multidisciplinary team approach.
-Ends-
For further information please contact:
Spire Healthcare Cora McCallum, Head of Investor Relations
| +44 (0)20 7427 9169 |
Instinctif Partners Damian Reece Guy Scarborough | +44 (0)20 7457 2020 |
Registered Office and Head Office:
Spire Healthcare Group plc
3 Dorset Rise
LondonEC4Y 8EN
Registered number 09084066
About Spire Healthcare
Spire Healthcare is a leading independent hospital group in the United Kingdom, with 39 private hospitals and 8 clinics across England, Wales and Scotland.
Spire Healthcare delivered tailored, personalised care to approximately 260,000 in-patients and daycase patients in 2018, and is the leading private provider, by volume, of knee and hip operations in the United Kingdom. The Group's well located and scalable hospitals have delivered successful and award-winning clinical outcomes, positioning the Group well with patients, consultants, the NHS, GPs and Private Medical Insurance ("PMI") providers. Spire treats patients through a variety of routes including PMI, Self-pay and the NHS, providing the Group with diversified access to the expected growth opportunities in the UK healthcare market, which faces significant supply challenges as a result of NHS budget constraints and increasing demand from a growing population with longer life expectancy.